Beta Bionics rated new Neutral at Baird on valuation
Baird has initiated its coverage of newly IPO’d medical device maker Beta Bionics (NASDAQ:BBNX) with a Neutral recommendation ...
Fintel on MSN1d
Baird Upgrades Amplitude (AMPL)
Fintel reports that on February 20, 2025, Baird upgraded their outlook for Amplitude (NasdaqCM:AMPL) from Neutral to ...
Amplitude upgraded to Outperform from Neutral at Baird
Baird upgraded Amplitude (AMPL) to Outperform from Neutral with a price target of $17, up from $12. The company reported solid Q4 results, ...
Watsco price target raised to $560 from $540 at Baird
Baird raised the firm’s price target on Watsco (WSO) to $560 from $540 and keeps an Outperform rating on the shares. The firm updated its model ...
Morningstar16d
Baird Aggregate Bond Inst
Citing the difficulty of predicting interest-rate changes consistently, Baird’s approach begins with matching this fund’s overall interest-rate sensitivity, or duration, to the Bloomberg US ...